TRAXNasdaqPharmaceutical PreparationsFiscal year ends December 31
First Tracks Biotherapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$36.28+1.82 (+5.28%)
Close on Oct 19, 2026
- Market cap
- $1.27B
- P/E (TTM)
- –
- Dividend yield
- –
Community
Notes and questions about First Tracks Biotherapeutics from other investors
No posts about TRAX yet
Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.